Trademark: 79180936
Word
ORPHAZYME
Status Date
Friday, August 25, 2023
Registration Number
5139414
Registration Date
Tuesday, February 14, 2017
Filing Date
Tuesday, December 1, 2015
Published for Opposition
Tuesday, November 29, 2016
Cancellation Date
Friday, August 25, 2023
5 Pharmaceutical and medical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; chemical-pharmaceutical preparations for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; diagnostic preparations for medical purposes; reagents for medical purposes and for research; preparations for analysis for medical and research purposes for the treatment of rare and genetic diseases, for the treatment of diseases involving protein misfolding, for the treatment of diseases involving lysosomal pathology, for the treatment of disorders of the central nervous system, for the treatment of neurodegenerative diseases, for the treatment of neuropsychiatric disorders, for the treatment of movement disorders, for the treatment of parkinsonism and Parkinson's disease, for the treatment of Amyotrophic lateral sclerosis (ALS), motor neuron disease (MND) and Lysosomal storage diseases (LSD) and for the treatment of Niemann-Pick disease type C, for the treatment of diseases associated with dysregulation of cholesterol homeostasis, cholesterol trafficking, cholesterol metabolism and cholesterol biosynthesis and for the treatment of atherosclerosis; all of the aforementioned with the exclusion of veterinary preparations and ingredients, supplements for food, and medicated foodstuffs for animals
1 Chemicals used in industry and in science; proteins for use in science and in manufacture; biochemicals, namely, polypeptides for scientific, research and commercial use; with the exclusion of chemicals used in the food industry and animal food industry and ingredients for foodstuffs for animals
42 Industrial analysis and research services; basic research and clinical research, hereunder for medicine and vaccine development; all the aforementioned services with the exclusion of services relating to the veterinary sector
Mar 21, 2016
Assigned To Examiner
Jan 21, 2016
Sn Assigned For Sect 66a Appl From Ib
Jan 28, 2016
New Application Office Supplied Data Entered
Feb 2, 2016
Application Filing Receipt Mailed
Mar 25, 2016
Non-Final Action Written
Mar 25, 2016
Non-Final Action Written
Mar 26, 2016
Non-Final Action (Ib Refusal) Prepared For Review
Mar 28, 2016
Refusal Processed By Mpu
Mar 28, 2016
Non-Final Action Mailed - Refusal Sent To Ib
May 13, 2016
Refusal Processed By Ib
Sep 26, 2016
Teas Response To Office Action Received
Oct 2, 2016
Assigned To Lie
Oct 5, 2016
Teas/Email Correspondence Entered
Oct 5, 2016
Correspondence Received In Law Office
Nov 9, 2016
Notification Of Notice Of Publication E-Mailed
Nov 29, 2016
Published For Opposition
Nov 29, 2016
Official Gazette Publication Confirmation E-Mailed
Feb 14, 2017
Registered-Principal Register
May 14, 2017
Final Disposition Notice Created, To Be Sent To Ib
Jun 1, 2017
Final Disposition Processed
Oct 18, 2016
Approved For Pub - Principal Register
Oct 22, 2016
Law Office Publication Review Completed
Dec 22, 2016
New Representative At Ib Received
Mar 2, 2017
New Representative At Ib Received
Jun 1, 2017
Final Disposition Notice Sent To Ib
May 5, 2021
Teas Change Of Owner Address Received
May 5, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 5, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
May 5, 2021
Teas Change Of Domestic Representatives Address
May 5, 2021
Teas Change Of Correspondence Received
May 5, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 8, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 23, 2017
Final Decision Transaction Processed By Ib
Aug 31, 2017
New Representative At Ib Received
Mar 30, 2018
Change Of Name/Address Rec'd From Ib
Sep 7, 2018
Teas Change Of Correspondence Received
Jan 25, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 25, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 8, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 8, 2021
Teas Withdrawal Of Attorney Received-Firm Retains
Jun 8, 2021
Teas Change Of Domestic Representatives Address
Jun 8, 2021
Teas Change Of Correspondence Received
Feb 14, 2022
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Jul 10, 2022
New Representative At Ib Received
Jun 12, 2021
New Representative At Ib Received
Apr 25, 2024
Total Invalidation Of Reg Ext Protection Created
May 6, 2024
Invalidation Processed
May 6, 2024
Total Invalidation Of Reg Ext Protection Sent To Ib
Aug 25, 2023
Cancelled Section 71
Trademark Alertz updated from USPTO on 2030-01-24
